For the Inventor, By the Inventor

Enter assignee name

Eisai R&d Management Co., Ltd.

USPTO Granted Patents = 527

CIPO Patents = 437

EPO Patents = 307

Trademarks = 62

Forward Citations = 3,188

Loading Chart...

Loading Chart...

1,357 inventors (with patents filed for the assignee):

Francis Gerard Fang (51 out of 67 patents)

Atsushi Endo (30 out of 30 patents)

Charles E Chase (30 out of 30 patents)

4. Keigo Tanaka (26 out of 30 patents)

5. Lynn D Hawkins (24 out of 33 patents)

6. Koichi Ito (21 out of 35 patents)

7. Hyeong-wook Choi (20 out of 23 patents)

8. Toshihiko Kaneko (19 out of 65 patents)

9. Mamoru Takaishi (18 out of 18 patents)

10. Nobuaki Sato (17 out of 24 patents)

11. Yuichi Ono (17 out of 18 patents)

12. Noritaka Kitazawa (17 out of 26 patents)

13. Dae-Shik Kim (15 out of 15 patents)

14. Yoshimasa Sakamoto (15 out of 16 patents)

15. Toshio Imai (15 out of 25 patents)

Core Competencies:

Orexin-2 Receptor Antagonist

Double-Stranded Ribonucleic Acid

Diazabicyclo Compounds

Breast Cancer Therapeutics

Hepatocyte Growth Factor

Tumor-Treating Compositions

Splicing Modulator Antibody-Drug Conjugates

PD-1 Antagonists

EZH2 Inhibitors

Macrocyclic Compounds

Cancer Combination Therapies

Anti-Tau Antibodies

527 patents: Sort by Forward Citations

1. 12479819 - Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities (2025-11-25),

2. 12447173 - Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5 (2025-10-21),

3. 12421248 - Macrocyclic compound and uses thereof (2025-09-23),

4. 12421246 - Method for synthesis of diazabicyclo[6.2.0]decane related compounds (2025-09-23),

5. 12414945 - Therapeutic agent for breast cancer (2025-09-16),

6. 12384824 - Method for producing an active hepatocyte growth factor (HGF) (2025-08-12),

7. 12364690 - Therapeutic agent for bile duct cancer (2025-07-22),

8. 12303505 - Tumor-treating pharmaceutical composition (2025-05-20),

9. 12303499 - Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds (2025-05-20),

10. 12253526 - Fluorescent dye and use thereof (2025-03-18),

11. 12251394 - Methods for the treatment of bladder cancer (2025-03-18),

12. 12251386 - Salt form of a human histone methyltransferase EZH2 inhibitor (2025-03-18),

13. D1066682 - Charging unit for a health condition monitoring system (2025-03-11),

14. 12226409 - Treatment of hepatocellular carcinoma (2025-02-18),

15. 12220398 - Tumor therapeutic agent (2025-02-11),

Eisai R&D Management Co., Ltd. is a leading global pharmaceutical company specializing in research and development. With a focus on innovation, they strive to create new therapeutic solutions that address unmet medical needs and improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

527 Patents

#157 in Tokyo

#359 in Japan

#1,796 in the World

Eisai R&d Management Co., Ltd.

Forward Citations = 3,188

1,357 inventors:

Francis Gerard Fang (51 out of 67 patents)

Atsushi Endo (30 out of 30 patents)

Charles E Chase (30 out of 30 patents)

4. Keigo Tanaka (26 out of 30 patents)

5. Lynn D Hawkins (24 out of 33 patents)

Please report any incorrect information to support@idiyas.com

Loading…